SCHEMBL6032173

SCHEMBL6032173

CCOC1SC(=O)N(Cc2ccccc2)C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
THRB P10828 2/20 0.54
GAA P10253 1/20 0.54
POLB P06746 1/20 0.52
TP53 P04637 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 4/20 0.44
ELANE P08246 3/20 0.43
F2 P00734 1/20 0.43
PLG P00747 1/20 0.43
CTSG P08311 1/20 0.43
CMA1 P23946 1/20 0.43
CTRC Q99895 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
EP300 Q09472 1/20 0.42
EHMT2 Q96KQ7 1/20 0.41
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469304 0.85 POLB (0.55) MAPTTHRBGAAPOLBTP53
SCHEMBL3774754 0.81 MAPT (0.50) MAPTTHRBGAAPOLBTP53
SCHEMBL8471742 0.78 MAPT (0.41) MAPTTHRBGAAPOLBTP53
SCHEMBL8523889 0.77 POLB (0.47) MAPTTHRBGAAPOLBTP53
SCHEMBL8421439 0.77 PPARG (0.43) MAPTTHRBGAAPOLBTP53
SCHEMBL8472109 0.77 MAPT (0.42) MAPTTHRBGAAPOLBTP53
SCHEMBL8472017 0.77 POLB (0.45) MAPTTHRBGAAPOLBTP53
Hydrochloric Acid SCHEMBL8505855 0.76 PPARG (0.44) MAPTTHRBGAAPOLBTP53
SCHEMBL3774750 0.76 POLB (0.46) MAPTTHRBGAAPOLBTP53
SCHEMBL8687366 0.76 POLB (0.44) MAPTTHRBGAAPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052627-A1 Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-03-09 US disclosed
EP-1332142-A1 SODIUM SALTS OF 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]B ENZYL]THIAZOLIDINE-2,4-DIONE SmithKline Beecham p.l.c. (GB) 2003-08-06 EP disclosed
WO-2002026735-A1 SODIUM SALTS OF 5-'4-'2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE SMITHKLINE BEECHAM P.L.C. (GB) 2002-04-04 WO disclosed
EP-0555249-A1 THIAZOLIDINEDIONE DERIVATIVES BEECHAM GROUP plc (GB) 1993-08-18 EP disclosed
US-4725610-A TREATMENT OF HYPERLIPEMIA AND DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052627-A1 Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA MAPT 3674/4885THRB 370/4885GAA 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.